Keenan LLC Makes New Investment in Astrazeneca Plc $AZN

Keenan LLC purchased a new position in shares of Astrazeneca Plc (NYSE:AZN) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 4,532 shares of the company’s stock, valued at approximately $795,000. Astrazeneca makes up 0.7% of Keenan LLC’s holdings, making the stock its 24th largest position.

A number of other institutional investors have also modified their holdings of the company. S Harris Financial Group LLC purchased a new position in Astrazeneca during the 4th quarter valued at about $1,291,000. EJMK Ventures LLC purchased a new stake in Astrazeneca during the fourth quarter worth about $1,623,000. Bank of Hawaii increased its stake in Astrazeneca by 6.8% during the fourth quarter. Bank of Hawaii now owns 18,756 shares of the company’s stock worth $3,292,000 after purchasing an additional 1,196 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in shares of Astrazeneca by 5.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,387 shares of the company’s stock worth $419,000 after purchasing an additional 133 shares in the last quarter. Finally, Reflection Asset Management acquired a new stake in shares of Astrazeneca during the fourth quarter worth about $31,000. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of research reports. TD Cowen restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Barclays reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. Finally, Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Astrazeneca currently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Stock Down 0.0%

AZN stock opened at $174.87 on Friday. The company’s 50 day moving average price is $186.62 and its 200 day moving average price is $186.27. The firm has a market capitalization of $271.20 billion, a price-to-earnings ratio of 26.26, a PEG ratio of 1.52 and a beta of 0.25. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The company had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. On average, equities research analysts anticipate that Astrazeneca Plc will post 9.39 EPS for the current fiscal year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.